Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 56 entries
Sorted by: Best Match Show Resources per page
Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.

Nature medicine

Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S.
PMID: 30705421
Nat Med. 2019 Mar;25(3):530. doi: 10.1038/s41591-019-0369-7.

In the version of this article originally published, the color key in Fig. 1a was wrong. In the Cytogenetics key, the box over t(8;21) originally was green. It should have been red, matching the color of the sections of...

Cite
Bolouri H, Farrar JE, Triche T, et al. Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2019;25(3):530doi: 10.1038/s41591-019-0369-7.
Bolouri, H., Farrar, J. E., Triche, T., Ries, R. E., Lim, E. L., Alonzo, T. A., Ma, Y., Moore, R., Mungall, A. J., Marra, M. A., Zhang, J., Ma, X., Liu, Y., Liu, Y., Auvil, J. M. G., Davidsen, T. M., Gesuwan, P., Hermida, L. C., Salhia, B., Capone, S., Ramsingh, G., Zwaan, C. M., Noort, S., Piccolo, S. R., Kolb, E. A., Gamis, A. S., Smith, M. A., Gerhard, D. S., & Meshinchi, S. (2019). Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature medicine, 25(3), 530. https://doi.org/10.1038/s41591-019-0369-7
Bolouri, Hamid, et al. "Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions." Nature medicine vol. 25,3 (2019): 530. doi: https://doi.org/10.1038/s41591-019-0369-7
Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S. Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2019 Mar;25(3):530. doi: 10.1038/s41591-019-0369-7. PMID: 30705421; PMCID: PMC7747938.
Copy Download .nbib Format: NLM
RNAIndel: discovering somatic coding indels from tumor RNA-Seq data.

Bioinformatics (Oxford, England)

Hagiwara K, Ding L, Edmonson MN, Rice SV, Newman S, Easton J, Dai J, Meshinchi S, Ries RE, Rusch M, Zhang J.
PMID: 31593214
Bioinformatics. 2020 Mar 01;36(5):1382-1390. doi: 10.1093/bioinformatics/btz753.

MOTIVATION: Reliable identification of expressed somatic insertions/deletions (indels) is an unmet need due to artifacts generated in PCR-based RNA-Seq library preparation and the lack of normal RNA-Seq data, presenting analytical challenges for discovery of somatic indels in tumor transcriptome.RESULTS:...

Cite
Hagiwara K, Ding L, Edmonson MN, et al. RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. Bioinformatics. 2020;36(5):1382-1390doi: 10.1093/bioinformatics/btz753.
Hagiwara, K., Ding, L., Edmonson, M. N., Rice, S. V., Newman, S., Easton, J., Dai, J., Meshinchi, S., Ries, R. E., Rusch, M., & Zhang, J. (2020). RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. Bioinformatics (Oxford, England), 36(5), 1382-1390. https://doi.org/10.1093/bioinformatics/btz753
Hagiwara, Kohei, et al. "RNAIndel: discovering somatic coding indels from tumor RNA-Seq data." Bioinformatics (Oxford, England) vol. 36,5 (2020): 1382-1390. doi: https://doi.org/10.1093/bioinformatics/btz753
Hagiwara K, Ding L, Edmonson MN, Rice SV, Newman S, Easton J, Dai J, Meshinchi S, Ries RE, Rusch M, Zhang J. RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. Bioinformatics. 2020 Mar 01;36(5):1382-1390. doi: 10.1093/bioinformatics/btz753. PMID: 31593214; PMCID: PMC7523641.
Copy Download .nbib Format: NLM
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.

Biomarker research

Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Jenkins IC, Fang M, Huynh M, Kopecky KJ, List AF, Naru J, Radich JP, Stevens E, Willborg BE, Willman CL, Wood BL, Zhang Q, Meshinchi S, Stirewalt DL.
PMID: 32817791
Biomark Res. 2020 Aug 12;8:29. doi: 10.1186/s40364-020-00208-1. eCollection 2020.

BACKGROUND: The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage patients with acute myeloid leukemia for optimal therapies. Despite the identification of many prognostic factors, relatively few have...

Cite
Pogosova-Agadjanyan EL, Moseley A, Othus M, et al. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. Biomark Res. 2020;8:29doi: 10.1186/s40364-020-00208-1.
Pogosova-Agadjanyan, E. L., Moseley, A., Othus, M., Appelbaum, F. R., Chauncey, T. R., Chen, I. L., Erba, H. P., Godwin, J. E., Jenkins, I. C., Fang, M., Huynh, M., Kopecky, K. J., List, A. F., Naru, J., Radich, J. P., Stevens, E., Willborg, B. E., Willman, C. L., Wood, B. L., Zhang, Q., Meshinchi, S., & Stirewalt, D. L. (2020). AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. Biomarker research, 829. https://doi.org/10.1186/s40364-020-00208-1
Pogosova-Agadjanyan, Era L, et al. "AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report." Biomarker research vol. 8 (2020): 29. doi: https://doi.org/10.1186/s40364-020-00208-1
Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Jenkins IC, Fang M, Huynh M, Kopecky KJ, List AF, Naru J, Radich JP, Stevens E, Willborg BE, Willman CL, Wood BL, Zhang Q, Meshinchi S, Stirewalt DL. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. Biomark Res. 2020 Aug 12;8:29. doi: 10.1186/s40364-020-00208-1. eCollection 2020. PMID: 32817791; PMCID: PMC7425159.
Copy Download .nbib Format: NLM
A B-cell developmental gene regulatory network is activated in infant AML.

PloS one

Bolouri H, Ries R, Pardo L, Hylkema T, Zhou W, Smith JL, Leonti A, Loken M, Farrar JE, Triche TJ, Meshinchi S.
PMID: 34793513
PLoS One. 2021 Nov 18;16(11):e0259197. doi: 10.1371/journal.pone.0259197. eCollection 2021.

Infant Acute Myeloid Leukemia (AML) is a poorly-addressed, heterogeneous malignancy distinguished by surprisingly few mutations per patient but accompanied by myriad age-specific translocations. These characteristics make treatment of infant AML challenging. While infant AML is a relatively rare disease,...

Cite
Bolouri H, Ries R, Pardo L, et al. A B-cell developmental gene regulatory network is activated in infant AML. PLoS One. 2021;16(11):e0259197doi: 10.1371/journal.pone.0259197.
Bolouri, H., Ries, R., Pardo, L., Hylkema, T., Zhou, W., Smith, J. L., Leonti, A., Loken, M., Farrar, J. E., Triche, T. J., & Meshinchi, S. (2021). A B-cell developmental gene regulatory network is activated in infant AML. PloS one, 16(11), e0259197. https://doi.org/10.1371/journal.pone.0259197
Bolouri, Hamid, et al. "A B-cell developmental gene regulatory network is activated in infant AML." PloS one vol. 16,11 (2021): e0259197. doi: https://doi.org/10.1371/journal.pone.0259197
Bolouri H, Ries R, Pardo L, Hylkema T, Zhou W, Smith JL, Leonti A, Loken M, Farrar JE, Triche TJ, Meshinchi S. A B-cell developmental gene regulatory network is activated in infant AML. PLoS One. 2021 Nov 18;16(11):e0259197. doi: 10.1371/journal.pone.0259197. eCollection 2021. PMID: 34793513; PMCID: PMC8601427.
Copy Download .nbib Format: NLM
Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin.

Haematologica

Lamba JK, Meshinchi S.
PMID: 34092060
Haematologica. 2021 Nov 01;106(11):2796-2798. doi: 10.3324/haematol.2021.279043.

No abstract available.

Cite
Lamba JK, Meshinchi S. Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin. Haematologica. 2021;106(11):2796-2798doi: 10.3324/haematol.2021.279043.
Lamba, J. K., & Meshinchi, S. (2021). Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin. Haematologica, 106(11), 2796-2798. https://doi.org/10.3324/haematol.2021.279043
Lamba, Jatinder K, and Meshinchi, Soheil. "Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin." Haematologica vol. 106,11 (2021): 2796-2798. doi: https://doi.org/10.3324/haematol.2021.279043
Lamba JK, Meshinchi S. Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin. Haematologica. 2021 Nov 01;106(11):2796-2798. doi: 10.3324/haematol.2021.279043. PMID: 34092060; PMCID: PMC8561291.
Copy Download .nbib Format: NLM
CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes.

Blood advances

Huang BJ, Smith JL, Wang YC, Taghizadeh K, Leonti AR, Ries RE, Liu Y, Kolekar P, Tarlock K, Gerbing R, Crowgey E, Furlan SN, Shaw TI, Hagiwara K, Wei L, Cooper TM, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche T, Alonzo TA, Ma X, Meshinchi S.
PMID: 34547772
Blood Adv. 2021 Dec 14;5(23):4963-4968. doi: 10.1182/bloodadvances.2021004965.

No abstract available.

Cite
Huang BJ, Smith JL, Wang YC, et al. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood Adv. 2021;5(23):4963-4968doi: 10.1182/bloodadvances.2021004965.
Huang, B. J., Smith, J. L., Wang, Y. C., Taghizadeh, K., Leonti, A. R., Ries, R. E., Liu, Y., Kolekar, P., Tarlock, K., Gerbing, R., Crowgey, E., Furlan, S. N., Shaw, T. I., Hagiwara, K., Wei, L., Cooper, T. M., Gamis, A. S., Aplenc, R., Kolb, E. A., Farrar, J. E., Triche, T., Alonzo, T. A., Ma, X., & Meshinchi, S. (2021). CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood advances, 5(23), 4963-4968. https://doi.org/10.1182/bloodadvances.2021004965
Huang, Benjamin J, et al. "CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes." Blood advances vol. 5,23 (2021): 4963-4968. doi: https://doi.org/10.1182/bloodadvances.2021004965
Huang BJ, Smith JL, Wang YC, Taghizadeh K, Leonti AR, Ries RE, Liu Y, Kolekar P, Tarlock K, Gerbing R, Crowgey E, Furlan SN, Shaw TI, Hagiwara K, Wei L, Cooper TM, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche T, Alonzo TA, Ma X, Meshinchi S. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood Adv. 2021 Dec 14;5(23):4963-4968. doi: 10.1182/bloodadvances.2021004965. PMID: 34547772.
Copy Download .nbib Format: NLM
Estimation of upper and lower bounds of Gini coefficient by fuzzy data.

Data in brief

Ganjoei RA, Akbarifard H, Mashinchi M, Majid Jalaee Esfandabadi SA.
PMID: 32123714
Data Brief. 2020 Feb 14;29:105288. doi: 10.1016/j.dib.2020.105288. eCollection 2020 Apr.

The data presented in this paper are used to examine the uncertainty in macroeconomic variables and their impact on the Gini coefficient. Annual data for the period 2017 - 1996 are taken from the Bank of Iran website https://www.cbi.ir....

Cite
Ganjoei RA, Akbarifard H, Mashinchi M, et al. Estimation of upper and lower bounds of Gini coefficient by fuzzy data. Data Brief. 2020;29:105288doi: 10.1016/j.dib.2020.105288.
Ganjoei, R. A., Akbarifard, H., Mashinchi, M., & Majid Jalaee Esfandabadi, S. A. (2020). Estimation of upper and lower bounds of Gini coefficient by fuzzy data. Data in brief, 29105288. https://doi.org/10.1016/j.dib.2020.105288
Ganjoei, Reza Ashraf, et al. "Estimation of upper and lower bounds of Gini coefficient by fuzzy data." Data in brief vol. 29 (2020): 105288. doi: https://doi.org/10.1016/j.dib.2020.105288
Ganjoei RA, Akbarifard H, Mashinchi M, Majid Jalaee Esfandabadi SA. Estimation of upper and lower bounds of Gini coefficient by fuzzy data. Data Brief. 2020 Feb 14;29:105288. doi: 10.1016/j.dib.2020.105288. eCollection 2020 Apr. PMID: 32123714; PMCID: PMC7038473.
Copy Download .nbib Format: NLM
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem.

Cancer discovery

McLeod C, Gout AM, Zhou X, Thrasher A, Rahbarinia D, Brady SW, Macias M, Birch K, Finkelstein D, Sunny J, Mudunuri R, Orr BA, Treadway M, Davidson B, Ard TK, Chiao A, Swistak A, Wiggins S, Foy S, Wang J, Sioson E, Wang S, Michael JR, Liu Y, Ma X, Patel A, Edmonson MN, Wilkinson MR, Frantz AM, Chang TC, Tian L, Lei S, Islam SMA, Meyer C, Thangaraj N, Tater P, Kandali V, Ma S, Nguyen T, Serang O, McGuire I, Robison N, Gentry D, Tang X, Palmer LE, Wu G, Suh E, Tanner L, McMurry J, Lear M, Pappo AS, Wang Z, Wilson CL, Cheng Y, Meshinchi S, Alexandrov LB, Weiss MJ, Armstrong GT, Robison LL, Yasui Y, Nichols KE, Ellison DW, Bangur C, Mullighan CG, Baker SJ, Dyer MA, Miller G, Newman S, Rusch M, Daly R, Perry K, Downing JR, Zhang J.
PMID: 33408242
Cancer Discov. 2021 May;11(5):1082-1099. doi: 10.1158/2159-8290.CD-20-1230. Epub 2021 Jan 06.

Effective data sharing is key to accelerating research to improve diagnostic precision, treatment efficacy, and long-term survival in pediatric cancer and other childhood catastrophic diseases. We present St. Jude Cloud (https://www.stjude.cloud), a cloud-based data-sharing ecosystem for accessing, analyzing, and...

Cite
McLeod C, Gout AM, Zhou X, et al. St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discov. 2021;11(5):1082-1099doi: 10.1158/2159-8290.CD-20-1230.
McLeod, C., Gout, A. M., Zhou, X., Thrasher, A., Rahbarinia, D., Brady, S. W., Macias, M., Birch, K., Finkelstein, D., Sunny, J., Mudunuri, R., Orr, B. A., Treadway, M., Davidson, B., Ard, T. K., Chiao, A., Swistak, A., Wiggins, S., Foy, S., Wang, J., Sioson, E., Wang, S., Michael, J. R., Liu, Y., Ma, X., Patel, A., Edmonson, M. N., Wilkinson, M. R., Frantz, A. M., Chang, T. C., Tian, L., Lei, S., Islam, S. M. A., Meyer, C., Thangaraj, N., Tater, P., Kandali, V., Ma, S., Nguyen, T., Serang, O., McGuire, I., Robison, N., Gentry, D., Tang, X., Palmer, L. E., Wu, G., Suh, E., Tanner, L., McMurry, J., Lear, M., Pappo, A. S., Wang, Z., Wilson, C. L., Cheng, Y., Meshinchi, S., Alexandrov, L. B., Weiss, M. J., Armstrong, G. T., Robison, L. L., Yasui, Y., Nichols, K. E., Ellison, D. W., Bangur, C., Mullighan, C. G., Baker, S. J., Dyer, M. A., Miller, G., Newman, S., Rusch, M., Daly, R., Perry, K., Downing, J. R., & Zhang, J. (2021). St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer discovery, 11(5), 1082-1099. https://doi.org/10.1158/2159-8290.CD-20-1230
McLeod, Clay, et al. "St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem." Cancer discovery vol. 11,5 (2021): 1082-1099. doi: https://doi.org/10.1158/2159-8290.CD-20-1230
McLeod C, Gout AM, Zhou X, Thrasher A, Rahbarinia D, Brady SW, Macias M, Birch K, Finkelstein D, Sunny J, Mudunuri R, Orr BA, Treadway M, Davidson B, Ard TK, Chiao A, Swistak A, Wiggins S, Foy S, Wang J, Sioson E, Wang S, Michael JR, Liu Y, Ma X, Patel A, Edmonson MN, Wilkinson MR, Frantz AM, Chang TC, Tian L, Lei S, Islam SMA, Meyer C, Thangaraj N, Tater P, Kandali V, Ma S, Nguyen T, Serang O, McGuire I, Robison N, Gentry D, Tang X, Palmer LE, Wu G, Suh E, Tanner L, McMurry J, Lear M, Pappo AS, Wang Z, Wilson CL, Cheng Y, Meshinchi S, Alexandrov LB, Weiss MJ, Armstrong GT, Robison LL, Yasui Y, Nichols KE, Ellison DW, Bangur C, Mullighan CG, Baker SJ, Dyer MA, Miller G, Newman S, Rusch M, Daly R, Perry K, Downing JR, Zhang J. St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discov. 2021 May;11(5):1082-1099. doi: 10.1158/2159-8290.CD-20-1230. Epub 2021 Jan 06. PMID: 33408242; PMCID: PMC8102307.
Copy Download .nbib Format: NLM
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research

Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, Loken MR, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S.
PMID: 34380639
Clin Cancer Res. 2021 Oct 15;27(20):5718-5730. doi: 10.1158/1078-0432.CCR-21-1546. Epub 2021 Aug 11.

PURPOSE: We previously identified mesothelin (MSLN) as highly expressed in a significant fraction of acute myeloid leukemia (AML) but entirely silent in normal hematopoiesis, providing a promising antigen for immunotherapeutic targeting that avoids hematopoietic toxicity. Given that T cells...

Cite
Le Q, Castro S, Tang T, et al. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clin Cancer Res. 2021;27(20):5718-5730doi: 10.1158/1078-0432.CCR-21-1546.
Le, Q., Castro, S., Tang, T., Loeb, A. M., Hylkema, T., McKay, C. N., Perkins, L., Srivastava, S., Call, L., Smith, J., Leonti, A., Ries, R., Pardo, L., Loken, M. R., Correnti, C., Fiorenza, S., Turtle, C. J., Riddell, S., Tarlock, K., & Meshinchi, S. (2021). Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(20), 5718-5730. https://doi.org/10.1158/1078-0432.CCR-21-1546
Le, Quy, et al. "Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,20 (2021): 5718-5730. doi: https://doi.org/10.1158/1078-0432.CCR-21-1546
Le Q, Castro S, Tang T, Loeb AM, Hylkema T, McKay CN, Perkins L, Srivastava S, Call L, Smith J, Leonti A, Ries R, Pardo L, Loken MR, Correnti C, Fiorenza S, Turtle CJ, Riddell S, Tarlock K, Meshinchi S. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clin Cancer Res. 2021 Oct 15;27(20):5718-5730. doi: 10.1158/1078-0432.CCR-21-1546. Epub 2021 Aug 11. PMID: 34380639.
Copy Download .nbib Format: NLM
Stoichiometry and Structure of Poly(amidoamine) Dendrimer-Lipid Complexes.

ACS nano

Kelly CV, Liroff MG, Triplett LD, Leroueil PR, Mullen DG, Wallace JM, Meshinchi S, Baker JR, Orr BG, Banaszak Holl MM.
PMID: 19534489
ACS Nano. 2009 Jul 28;3(7):1886-96. doi: 10.1021/nn900173e. Epub 2009 Jun 17.

The energetics, stoichiometry, and structure of poly(amidoamine) (PAMAM) dendrimer-phospholipid interactions were measured with isothermal titration calorimetry (ITC), transmission electron microscopy (TEM), atomic force microscopy (AFM), dynamic light scattering (DLS), and molecular dynamics (MD) simulations. Dendrimers of sixth-generation and smaller...

Cite
Kelly CV, Liroff MG, Triplett LD, et al. Stoichiometry and Structure of Poly(amidoamine) Dendrimer-Lipid Complexes. ACS Nano. 2009;3(7):1886-96doi: 10.1021/nn900173e.
Kelly, C. V., Liroff, M. G., Triplett, L. D., Leroueil, P. R., Mullen, D. G., Wallace, J. M., Meshinchi, S., Baker, J. R., Orr, B. G., & Banaszak Holl, M. M. (2009). Stoichiometry and Structure of Poly(amidoamine) Dendrimer-Lipid Complexes. ACS nano, 3(7), 1886-96. https://doi.org/10.1021/nn900173e
Kelly, Christopher V, et al. "Stoichiometry and Structure of Poly(amidoamine) Dendrimer-Lipid Complexes." ACS nano vol. 3,7 (2009): 1886-96. doi: https://doi.org/10.1021/nn900173e
Kelly CV, Liroff MG, Triplett LD, Leroueil PR, Mullen DG, Wallace JM, Meshinchi S, Baker JR, Orr BG, Banaszak Holl MM. Stoichiometry and Structure of Poly(amidoamine) Dendrimer-Lipid Complexes. ACS Nano. 2009 Jul 28;3(7):1886-96. doi: 10.1021/nn900173e. Epub 2009 Jun 17. PMID: 19534489; PMCID: PMC2888816.
Copy Download .nbib Format: NLM
Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.

Pediatric blood & cancer

Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch B, Loken M, Brodersen LE, Kahwash S, Choi J, Kolb EA, Gamis A, Aplenc R.
PMID: 34472213
Pediatr Blood Cancer. 2022 Jan;69(1):e29313. doi: 10.1002/pbc.29313. Epub 2021 Sep 02.

BACKGROUND: The optimal number of chemotherapy courses for low-risk (LR) pediatric acute myeloid leukemia (AML) is not known.OBJECTIVE: To compare outcomes for four (21.6 g/mMETHODS: We compared relapse risk (RR), disease-free survival (DFS), and overall survival (OS), and the...

Cite
Getz KD, Alonzo TA, Sung L, et al. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021;69(1):e29313doi: 10.1002/pbc.29313.
Getz, K. D., Alonzo, T. A., Sung, L., Meshinchi, S., Gerbing, R. B., Raimondi, S., Hirsch, B., Loken, M., Brodersen, L. E., Kahwash, S., Choi, J., Kolb, E. A., Gamis, A., & Aplenc, R. (2022). Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric blood & cancer, 69(1), e29313. https://doi.org/10.1002/pbc.29313
Getz, Kelly D, et al. "Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group." Pediatric blood & cancer vol. 69,1 (2022): e29313. doi: https://doi.org/10.1002/pbc.29313
Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch B, Loken M, Brodersen LE, Kahwash S, Choi J, Kolb EA, Gamis A, Aplenc R. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 Jan;69(1):e29313. doi: 10.1002/pbc.29313. Epub 2021 Sep 02. PMID: 34472213.
Copy Download .nbib Format: NLM
CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

JCO precision oncology

Chauhan L, Shin M, Wang YC, Loken M, Pollard J, Aplenc R, Hirsch BA, Raimondi S, Ries RE, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S, Lamba JK.
PMID: 32914031
JCO Precis Oncol. 2019 May 23;3. doi: 10.1200/PO.18.00387. eCollection 2019.

PURPOSE: The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop strategies for effective use of GO. In light of our recent...

Cite
Chauhan L, Shin M, Wang YC, et al. CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. JCO Precis Oncol. 2019;3doi: 10.1200/PO.18.00387.
Chauhan, L., Shin, M., Wang, Y. C., Loken, M., Pollard, J., Aplenc, R., Hirsch, B. A., Raimondi, S., Ries, R. E., Bernstein, I. D., Gamis, A. S., Alonzo, T. A., Meshinchi, S., & Lamba, J. K. (2019). CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. JCO precision oncology, 3. https://doi.org/10.1200/PO.18.00387
Chauhan, Lata, et al. "CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/PO.18.00387
Chauhan L, Shin M, Wang YC, Loken M, Pollard J, Aplenc R, Hirsch BA, Raimondi S, Ries RE, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S, Lamba JK. CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. JCO Precis Oncol. 2019 May 23;3. doi: 10.1200/PO.18.00387. eCollection 2019. PMID: 32914031; PMCID: PMC7446480.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 56 entries